PATENT CLAIM ANALYSIS

Application Number: 16245682
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "023000"]

Abstract:
The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example Type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example NASH, NAFLD, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (MACE) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span.

Claim (Index 15):
The method of  claim 50 , wherein the subject in need thereof is overweight or obese; and wherein the subject in need thereof has been diagnosed with or exhibits one or more symptoms of a disorder selected from the group consisting of pre-diabetes, impaired oral glucose tolerance, Type II diabetes mellitus, Metabolic Syndrome, cardiovascular risk, renal or fatty liver disorder and sleep apnea.

Metadata:
- Claim Count in Document: 137.0
- Percentile: 99.0
- Lexical Diversity: 2.23256
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14048576', '14495246', '15639972', '14509297', '12481540']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7555118333658295
- 35 USC 102 Novelty (BERT): 0.5039563906831785
- Combined Prediction Score: 0.7303562890975644
- Mean Citation Score: 220.874216
- Max Citation Score: 224.14459
- Similarity Product: 152.84575116008517

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test